HRS-4357
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook · registrational
Metastatic Castration-Resistant Prostate Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other PSMA drugs
225Ac-PSMA-617, Zadavotide guraxetan, HRS-1738, SHR-4394. Compare all 5 PSMA drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HRS-4357: this drug | Phase 3 | Undisclosed | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Partial signal | No reviewed efficacy summary in this indication | |
| Talazoparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| 225Ac-PSMA-617 | Phase 3(overall) | Radioligand Therapy (actinium-225) | PSMA | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Elfetabart Drozuntecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Fluzoparib | Phase 3 | Small molecule | PARP (poly ADP-ribose polymerase), specifically PARP-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mevrometostat | Phase 3 | Small molecule | EZH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Opevesostat | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Pasritamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Zadavotide Guraxetan | Phase 3 | Radioconjugate (actinium-225) | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Luxdegalutamide | Phase 2 | Small molecule | Androgen receptor, Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-1738 | Phase 1/2(overall) | Undisclosed | PSMA | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SHR-4394 | Phase 1/2(overall) | Antibody–drug conjugate | PSMA | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-969 | Phase 1 | Undisclosed | PSMA / STEAP1 | not yet graded | No reviewed efficacy summary in this indication | |
| AKY-2519 | Phase 1 | Radiopharmaceutical | B7-H3-targeted radioligand therapy | not yet graded | No reviewed efficacy summary in this indication | |
| BPX-601 | Phase 1 | Cell therapy | PSCA | not yet graded | No reviewed efficacy summary in this indication | |
| RG6852 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow HRS-4357 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.